HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of pupillary block component in angle-closure glaucoma.

Abstract
To evaluate the amount of the pupillary block component in primary angle-closure glaucoma, the dark-room prone-position test was carried out in 30 eyes of 20 primary angle-closure glaucoma patients, before and one month after argon laser iridotomy. The pupillary block component in the prone position (5.8 +/- 5.6 mmHg), which is the amount of reduction in IOP rise in the post-laser dark-room prone-position test, composed 67.8% of the IOP rise in the pre-laser dark-room prone-position test (8.6 +/- 5.6 mmHg). The amount of the pupillary block component correlated significantly with the IOP rise in the pre-laser dark-room prone-position test (r = 0.880, P < 0.001). The amount of the non-pupillary block component was relatively constant and correlated poorly with the IOP rise in the pre-laser dark-room prone-position test (r = 0.163, P = 0.386). The pupillary block component was significantly larger than the non-pupillary block component in the eyes with an IOP rise of > or = 7 mmHg in the pre-laser dark-room prone-position test (P < 0.01). The dark-room prone-position test could be useful in evaluating the pupillary block component in angle-closure glaucoma eyes and helpful in making a decision for laser iridotomy.
AuthorsC Hong, K H Park, S M Hyung, K Y Song, D M Kim, D H Youn
JournalJapanese journal of ophthalmology (Jpn J Ophthalmol) Vol. 40 Issue 2 Pg. 239-43 ( 1996) ISSN: 0021-5155 [Print] Japan
PMID8876393 (Publication Type: Journal Article)
Topics
  • Adult
  • Aged
  • Dark Adaptation
  • Female
  • Glaucoma, Angle-Closure (physiopathology, surgery)
  • Humans
  • Intraocular Pressure
  • Iris (surgery)
  • Laser Therapy
  • Male
  • Middle Aged
  • Prone Position
  • Pupil (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: